47 Results for "

phosphorylated ERK

" in MedChemExpress (MCE) Product Catalog:
Products (47)

47 Results for "phosphorylated ERK" in MCE Product Catalog:

57
57 Publications Verification
Cat. No.: HY-15816
CAS No.: 869886-67-9
Purity:  99.95%
Synonyms: BVD-523; VRT752271
Target:  

ERK

Research Areas:  

Cancer

Ulixertinib (BVD-523; VRT752271) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases, with an IC50 of <0.3 nM against ERK2. Ulixertinib (BVD-523; VRT752271) inhibits the phosphorylated ERK2 (pERK) and downstream kinase RSK (pRSK) in an A375 melanoma cell line .
loading...
    loading...
57
57 Publications Verification
Cat. No.: HY-15816A
CAS No.: 1956366-10-1
Purity:  99.89%
Synonyms: BVD-523 hydrochloride; VRT752271 hydrochloride
Target:  

ERK

Research Areas:  

Cancer

Ulixertinib hydrochloride (BVD-523 hydrochloride) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases, with an IC50 of <0.3 nM against ERK2. Ulixertinib hydrochloride inhibits the phosphorylated ERK2 (pERK) and downstream kinase RSK (pRSK) in an A375 melanoma cell line .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-119272
CAS No.: 342808-40-6
Purity:  99.34%
EF24, a curcumin analogue, is an NF-kB inhibitor with great anti-tumor efficacy and oral bioavailability via deactivation of the MAPK/ERK signaling pathway in oral squamous cell carcinoma (OSCC). EF24 is active against melanoma and breast cancer cell lines with GI50 values of 0.7 μM and 0.8 μM, respectively. EF24 induces cell cycle arrest and apoptosis in MDA-MB-231 human breast cancer cells and DU-145 human prostate cancer cells. EF24 increases the levels of activated caspase 3 and 9, and decreases the phosphorylated forms of MEK1 and ERK .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-12736A
CAS No.: 2341796-81-2
Purity:  99.37%
Target:  

Syk ERK

Research Areas:  

Inflammation/Immunology Cancer

GSK143 dihydrochloride is an orally active and highly selective spleen tyrosine kinase (SYK) inhibitor with a pIC50 of 7.5. GSK143 dihydrochloride inhibits phosphorylated Erk (pErk: pIC50=7.1) . GSK143 dihydrochloride reduces inflammation and prevents recruitment of immune cells in the intestinal muscularis in mice .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-124452
CAS No.: 26605-16-3
Purity:  95.00%
Synonyms: Desferrioxamine E; Nocardamin
Nocardamine (Desferrioxamine E; Nocardamin) is a cyclic trihydroxamate siderophore with iron ion chelation, antioxidant, antibacterial and other activities. Nocardamine is synthesized by Pseudomonas stutzeri under iron-deficient conditions, and excessive iron ions significantly inhibit its biosynthesis process. Nocardamine increases the level of phosphorylated ERK protein, promotes nuclear translocation of β-catenin, and restores the downregulated expression of SIRT1 protein. Nocardamine alleviates cellular oxidative stress, reduces ROS content, and simultaneously repairs the ability to form mineralized nodules and the expression of osteogenic markers. Nocardamine induces FoxA gene transcription and protein expression to assist Pseudomonas aeruginosa in iron ion uptake; it also selectively inhibits the proliferation of mycobacteria. Nocardamine induces spindle-shaped morphological changes in BM-N4 insect cells, and sufficient iron ions inhibit this cellular morphological change. Nocardamine is suitable for research related to bacterial infections .
loading...
    loading...
Cat. No.: HY-156002
CAS No.: 2676177-63-0
Purity:  99.20%
Synonyms: Paluratide
Target:  

Ras ERK

Research Areas:  

Cancer

LUNA18 is an orally-available cyclic peptide KRAS and ERK inhibitor. LUNA18 phosphorylates ERK and AKT and decreases cell proliferation in RAS-mutated cancer cells. LUNA18 exhibits RAS signal inhibition and potent anti-cancer activities through inhibiting interaction between RAS and guanine nucleotide exchange factors (GEFs) in a mouse xenograft model. LUNA18 shows significant cellular efficacy against cell lines with KRAS genetic alterations, such as colon cancer, stomach cancer, non-small cell lung cancer and pancreaticcancer .
loading...
    loading...
Cat. No.: HY-W017982
CAS No.: 55965-84-9
Synonyms: CMI/MI
CMIT/MIT (14.5% in water) (CMI/MI) is a mixture of CMIT and MIT, and is also a preservative and skin sensitizer. CMIT/MIT (14.5% in water) increases the levels of phosphorylated ERK1/2, p38, JNK1/2, p53, p21 and Bax, decreases the level of Bcl-2, and activates the Nrf-2/HO-1 signaling pathway. CMIT/MIT (14.5% in water) increases LDH release and lipid peroxidation levels, impairs antioxidant defense capacity, promotes pro-inflammatory cytokine release, induces apoptosis, triggers cell cycle arrest, exhibits neurotoxicity in neuroblastoma cells, and causes dysregulation of Th2/Th17 immune responses. CMIT/MIT (14.5% in water) can be used in studies related to allergy, atopic dermatitis and lung injury .
loading...
    loading...
Cat. No.: HY-N9330
CAS No.: 162558-94-3
Broussoflavonol F is a potent dual inhibitor of the HER2-RAS-MEK-ERK signaling pathway and mushroom tyrosinase with an IC50 value of 82.3 μM. Broussoflavonol F downregulates the expression of RAS, HER2, phosphorylated BRAF, phosphorylated MEK and phosphorylated Erk proteins. Broussoflavonol F induces cell cycle arrest and apoptosis, and exhibits cytotoxicity in colon cancer cells. Broussoflavonol F inhibits endothelial proliferation, migration and tube formation, suppresses subintestinal vascular development, and reduces the mRNA levels of angiogenesis-associated genes.Broussoflavonol F can be used for colon cancer research .
loading...
    loading...
Cat. No.: HY-P10728
CAS No.: 1818415-56-3
B7-33 is a single-chain relaxin mimetic and a selective relaxin receptor 1 (RXFP1) agonist. B7-33 phosphorylates ERK1/2 without inducing activation of the cAMP signaling pathway. B7-33 exhibits anti-fibrotic and cardioprotective activities. B7-33 can be used in the research of vascular diseases such as cardiomyopathy, myocardial infarction and fibrosis .
loading...
    loading...
Cat. No.: HY-P990661

Target:  

c-Met/HGFR ERK PERK

Research Areas:  

Cancer

SAIT-301 is a Met-targeting monoclonal antibody. SAIT-301 inhibits Met activation, induces downregulated expression of phosphorylated Met(p-Met) and phosphorylated ERK(p-ERK), and reduces EGR-1 expression. SAIT-301 inhibits the migration and invasion of nasopharyngeal carcinoma cells. SAIT-301 is applicable to relevant research on nasopharyngeal carcinoma. For the isotype control of SAIT-301, refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
loading...
    loading...
Cat. No.: HY-116586
AF710B is an orally effective allosteric agonist for the M1 muscarinic receptor and σ1 receptor. AF710B activates the downstream phosphorylated ERK1/2 and phosphorylated CREB signaling pathways. AF710B simultaneously improves cognitive function and alleviates the core pathological features of Alzheimer's disease, including Aβ deposition, excessive Tau phosphorylation and neuroinflammation. AF710B is applicable to the research of Alzheimer's disease .
loading...
    loading...
Cat. No.: HY-15816R
CAS No.: 869886-67-9
Synonyms: BVD-523 (Standard); VRT752271 (Standard)
Target:  

ERK Reference Standards

Research Areas:  

Cancer

Ulixertinib (Standard) is the analytical standard of Ulixertinib. This product is intended for research and analytical applications. Ulixertinib (BVD-523; VRT752271) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases, with an IC50 of <0.3 nM against ERK2. Ulixertinib (BVD-523; VRT752271) inhibits the phosphorylated ERK2 (pERK) and downstream kinase RSK (pRSK) in an A375 melanoma cell line .
loading...
    loading...
Cat. No.: HY-156382
CAS No.: 2136270-56-7
Purity:  99.71%
Target:  

Akt ERK E1/E2/E3 Enzyme

Research Areas:  

Cancer

SPOP-IN-1 is a selective SPOP E3 ubiquitin ligase inhibitor. SPOP-IN-1 leads to the accumulation of tumor suppressors PTEN and DUSP7 and decreased levels of phosphorylated AKT and ERK in clear-cell renal cell carcinoma .
loading...
    loading...
Cat. No.: HY-N4309
CAS No.: 6871-67-6
Lotusine is an orally active signaling pathway modulator and enzyme inhibitor, with an IC50 of 30.60 μg/mL against α-amylase and an IC50 of 36.15 μg/mL against α-glucosidase. Lotusine inhibits the EGFR-Akt-ERK signaling pathway by reducing the levels of phosphorylated EGFR, Akt and ERK. Lotusine induces apoptosis, triggers G0/G1 cell cycle arrest and inhibits cancer cell proliferation. Lotusine reduces lipid peroxidation and increases the activities of SOD, CAT and GPx. Lotusine is applicable to researches related to non-small cell lung cancer, type 2 diabetes and autism spectrum disorder .
loading...
    loading...
Cat. No.: HY-P991664
AG01 is a monoclonal antibody against progranulin (GP88). AG01 inhibits triple-negative breast cancer (TNBC) cell proliferation and migration, reduces the expression of phosphorylated protein kinases p-Src, p-AKT, and p-ERK, and reduces the expression of oncogenic proteins such as Axl, c-MET, HIF-1α, and VEGF. AG01 inhibits tumor growth and Ki67 expression in a TNBC xenograft mouse model. AG01 can be used in the research of TNBC and other cancers .
loading...
    loading...
Cat. No.: HY-12736
CAS No.: 1240390-27-5
Target:  

Syk ERK

Research Areas:  

Inflammation/Immunology Cancer

GSK143 is an orally active and highly selective spleen tyrosine kinase (SYK) inhibitor with a pIC50 of 7.5. GSK143 inhibits phosphorylated Erk (pErk: pIC50=7.1) . GSK143 reduces inflammation and prevents recruitment of immune cells in the intestinal muscularis in mice .
loading...
    loading...
Cat. No.: HY-163709
Target:  

PROTACs FAK Akt ERK

Research Areas:  

Cancer

PROTAC FAK degrader 2 is an orally active PROTAC FAK degrader with a DC50 of 60.10 nM. PROTAC FAK degrader 2 forms a ternary complex with FAK and CRBN E3 ubiquitin ligase, driving proteasome-mediated degradation of total and phosphorylated FAK. PROTAC FAK degrader 2 inhibits phosphorylation of AKT and ERK, suppressing their downstream signaling pathways. PROTAC FAK degrader 2 reduces cancer cell viability, adhesion, migration, and invasion. PROTAC FAK degrader 2 exerts anti-tumor activity in HCT8/T tumor xenografts in mice. PROTAC FAK degrader 2 can be used for the research of breast cancer, colorectal cancer, lung cancer .
loading...
    loading...
Cat. No.: HY-131547
CAS No.: 13258-85-0
Purity:  99.7%
Synonyms: 10-Ethenyl-19-norprogesterone
Org OD 02-0 (10-Ethenyl-19-norprogesterone) is a selective mPRα/PAQR7 agonist that can cross the blood-brain barrier. Org OD 02-0 targets mPRα with an IC50 of 33.9 nM and activates the PI3K-AKT, MAPK/ERK, and Src signaling pathways. Org OD 02-0 upregulates SERCA2, phosphorylates phospholamban, increases sarcoplasmic reticulum calcium uptake, decreases RhoA/ROCK activity, and induces vascular smooth muscle relaxation and nitric oxide production. Org OD 02-0 can be used for research on Parkinson's disease, glioblastoma, apnea, and hypertension .
loading...
    loading...
Cat. No.: HY-E70746
Target:  

MEK

Research Areas:  

Cancer

MEK1 is the MAP/ERK kinase. The MEK1 kinase directly phosphorylates ERK2, after the activation loop of MEK1 is itself phosphorylated by Raf. MEK1 SESE is a mutant of MEK1. MEK1 SESE Recombinant Human Active Protein Kinase is a recombinant MEK1 SESE protein that can be used to study MEK1 SESE-related functions .
loading...
    loading...
Cat. No.: HY-P10421
CAS No.: 915155-20-3
Target:  

ERK

Research Areas:  

Cancer

PKCδ substrate acts as a nuclear transporter of ERK2 and is involved in ERK2 mediated gene activation. PKCδ is involved in the regulation of cell growth, proliferation, cell cycle arrest, and apoptosis by phosphorylating hBVR and other proteins. PKCδ substrate can be used to study the development of diseases, especially cancer biology .
loading...
    loading...